Maintenance Treatment in Advanced NSCLC
The current standard of care for first-line treatment of advanced non-small cell lung cancer (NSCLC) is a platinum-based doublet of cytotoxic drugs, combining a platinum agent to a chemotherapy agent such as gemcitabine, paclitaxel, docetaxel or pemetrexed.